by Lew Rockwell, Lew Rockwell:
Thymus Gland Hormone Demonstrably Raises T-Cell Counts, Slashes Deaths by 272% Among Severely-Ill COVID-19 Patients Without Side Effects; Also Could Be Cancer Cure; Can Be Mimicked With Zinc Pills
In an astounding study the public has not heard about, the subcutaneous (under the skin) injection of just 1.6 milligrams of a thymus gland hormone (thymosin alpha-1) for seven days among patients with severe deathbed COVID-19 coronavirus disease dramatically increases T-cell counts and slashes the mortality rate by 272% (from 30% to 11%) without side effects.
TRUTH LIVES on at https://sgtreport.tv/
This astonishing study, which emanates from Wuhan, China, the initial epicenter for the COVID-19 pandemic, indicates a life-saving remedy for severe COVID-19 coronavirus infections is at hand. The report, published in the journal Clinical Infectious Diseases, is a landmark study because of its demonstrable effect even among the most severely ill patients facing imminent death.
In a parallel study published in the journal International Immunopharmacology, short-term thymus gland hormone treatment (5 or more days) dramatically reduced survival at the 28-day point but not 60-day mortality, presumably because treatment was not continued.
In recent times it has become evident that T-cells (white blood cells produced in the thymus gland) are superior to antibodies in providing long-term immunity against infectious disease. T-memory cells not only activate antibodies but are able to “completely suppress viral replication or completely eradicate the virus.”
Thymus gland hormone (thymosin-A1), an approved therapy for infectious diseases and cancer, is posed as “hope out of the box in the COVID-19 disaster.”
Not for prevention
Thymosin-A1 injections are not beneficial for healthy patients who have adequate T-cell counts. So, the treatment will not serve to prevent any infectious disease including COVID-19, but exerts a demonstrable life-saving effect among severely ill patients. Side effects are reported from thymosin-A1 injections in healthy individuals.
Nothing done about age-related decline in thymus hormone
The immune system weakens with advancing age and little is done about that. Exhausted thymus gland hormone is the key reason for this age-related decline in immunity.
Produced in the thymus gland, thymosin-A1 is a natural and essential component of the human immune system. It is what the human body relies upon to fend off infectious diseases. Removal of the thymus gland results in mortality of laboratory animals.
Over a decade ago a report in Future Medicine claimed that “Thymosin-based therapies have the potential to treat the two most prevalent causes of death in the USA – cancer and cardiovascular disease.”
A more recent report “strongly recommended” thymosin-A1 among cancer patients undergoing chemotherapy. Thymosin-A1 is also posed as a “vaccine enhancer.” Thymosin-A1 can also be added to vaccines as an adjuvant.
Thymosin-A1 and cancer
Thymosin-A1 is an already-approved drug for immunodeficiency diseases and has direct therapeutic and even curative application as an anti-cancer treatment via its ability to minimize immune-suppression and inhibit cancer growth factors (vascular endothelial growth factor or VEGF) and therefore can also serve to avert vision loss from growth of abnormal blood vessels in the visual center of the eyes (macular degeneration).